Your Cart is Empty
April 8-13, 2022, Ernest N. Morial Convention Center, New Orleans, Louisiana
Come see us at Booth 2618.
I. Poster Abstract 625: Sunday, April 10, 2022, 1:30 – 5:00 p.m. – Poster Board No. 10
Immunophenotyping of TCR and BCR clonotypes
II. Poster Abstract 3426: Tuesday, April 12, 2022 – 1:30 – 5:00 p.m. – Poster Board No. 18
Perturb-seq analysis of TNFα-induced transcriptional response
III. Educational Symposium: Spotlight Theatre A, Tuesday, April 12, 2022, 3:00-4:00 p.m.
I won't be able to attend in person but am interested in receiving the recording of the talks
CRISPR & RNAi Genetic Screening and other Methods for the Discovery of Oncogenic Vulnerabilities and Drug Resistance
Moderator: Paul Diehl, PhD, COO, Cellecta
Speaker 1: Maria J. Ruiz-Echevarria, PhD, Associate Professor, Stephenson Cancer Center, Oklahoma Health Sciences Center
Talk: Development of a multitargeted therapy for prostate cancer
Relapse after first-line androgen deprivation therapy (ADT) is the main cause of mortality in patients with advanced prostate cancer (PCa). Key molecular mechanisms of resistance reveal continued activation of the androgen receptor (AR). To enable the development of multitargeted therapeutics for PCa, we have developed an unbiased RNA interference (RNAi) based negative selection screen to identify shRNAs that cause toxicity in cellular models of relapsed disease after ADT, by targeting multiple AR-signaling components. The results emphasize the value of this screen for the identification of effective multitarget therapeutic modalities that maximize AR signaling inhibition with theoretically limited resistance profiles.
Speaker 2: Alex Chenchik, PhD, President and Chief Scientific Officer, Cellecta
Talk: Immunophenotyping of TCR and BCR clonotypes
T-cell receptor (TCR) and B-cell receptor (BCR) repertoire profiling holds great potential for understanding the disease mechanisms and development of new therapeutics for infectious disease, auto-immunity and immuno-oncology applications. However, this potential could be greatly improved by combining information about receptor clonotypes with immunophenotypes of T and B cells. To facilitate these studies, we developed a novel technology for combined profiling of all human TCR and BCR variable regions and phenotypic characterization of immune cells.
Register to attend in person here. Refreshments will be provided. Space is limited.
I won't be able to attend in person but please send me the recording of the event.
